Scinai Immunotherapeutics (NASDAQ:SCNI) Issues Earnings Results

Scinai Immunotherapeutics (NASDAQ:SCNI) announced its quarterly earnings data on Wednesday. The company reported $0.94 EPS for the quarter, Zacks reports.

Scinai Immunotherapeutics Stock Performance

Scinai Immunotherapeutics stock traded down $0.03 during midday trading on Wednesday, hitting $0.32. 95,342 shares of the company were exchanged, compared to its average volume of 1,960,643. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.30 and a current ratio of 1.30. The firm has a market capitalization of $1.28 million, a PE ratio of -0.03 and a beta of 2.05. The business has a fifty day simple moving average of $0.54 and a two-hundred day simple moving average of $0.74. Scinai Immunotherapeutics has a fifty-two week low of $0.31 and a fifty-two week high of $3.48.

Institutional Trading of Scinai Immunotherapeutics

An institutional investor recently raised its position in Scinai Immunotherapeutics stock. Citadel Advisors LLC raised its position in Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 28,630 shares of the company’s stock after buying an additional 17,031 shares during the period. Citadel Advisors LLC owned about 0.90% of Scinai Immunotherapeutics worth $36,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 58.41% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.